Galapagos has announced collaboration agreements with Merck Serono.
The service division of Galapagos, Biofocus DPI, will provide Softfocus compounds for use in Merck Serono's drug discovery programmes.
In a separate agreement, Biofocus DPI will perform medicinal chemistry services on an undisclosed Merck Serono programme.
'Biofocus DPI has a long relationship with Merck Serono in medicinal chemistry, which we are pleased to extend again this year,' said Onno van de Stolpe, chief executive officer of Galapagos.
